| Literature DB >> 26468226 |
Stefano Volpi1, Elettra Santori2, Katrina Abernethy3, Masayuki Mizui4, Carin I M Dahlberg5, Mike Recher3, Kelly Capuder3, Eva Csizmadia6, Douglas Ryan3, Divij Mathew3, George C Tsokos4, Scott Snapper7, Lisa S Westerberg5, Adrian J Thrasher8, Fabio Candotti2, Luigi D Notarangelo9.
Abstract
Mutations of the Wiskott-Aldrich syndrome gene (WAS) are responsible for Wiskott-Aldrich syndrome (WAS), a disease characterized by thrombocytopenia, eczema, immunodeficiency, and autoimmunity. Mice with conditional deficiency of Was in B lymphocytes (B/WcKO) have revealed a critical role for WAS protein (WASP) expression in B lymphocytes in the maintenance of immune homeostasis. Neural WASP (N-WASP) is a broadly expressed homolog of WASP, and regulates B-cell signaling by modulating B-cell receptor (BCR) clustering and internalization. We have generated a double conditional mouse lacking both WASP and N-WASP selectively in B lymphocytes (B/DcKO). Compared with B/WcKO mice, B/DcKO mice showed defective B-lymphocyte proliferation and impaired antibody responses to T-cell-dependent antigens, associated with decreased autoantibody production and lack of autoimmune kidney disease. These results demonstrate that N-WASP expression in B lymphocytes is required for the development of autoimmunity of WAS and may represent a novel therapeutic target in WAS.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26468226 PMCID: PMC4713162 DOI: 10.1182/blood-2015-05-643817
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 25.476